Loading company…
Vera Therapeutics is a South San Francisco biotech developing treatments for IgA nephropathy and other immunological diseases.
Founded in 2016 by Marshall Fordyce and formerly known as Trucode Gene Repair, Inc., Vera Therapeutics develops therapies for immunological and inflammatory diseases, starting with IgA nephropathy, a rare autoimmune disease. Its lead candidate is atacicept, a novel inhibitor of B cells and plasma cells. The company raised USD 80 million in a Series C round led by Abingworth in January 2021, and in May 2021 it raised USD 47.85 million in an IPO, selling 4.35 million shares at USD 11 per share. It trades on the Nasdaq Global Market under the ticker VERA.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in